by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
10/7/2021
May 2021 Review of news from the most innovative therapeutic areas and the business development transactions
SOTIO
Market
Proposed new US Government body ARPA-H is raising both hopes and skepticism
Proposed new US government body Advanced Research Projects Agency – Health should be antidote to bureaucracy and incrementalism that some patient advocates believe prevents NIH from turning an investment of over $50 billion per year into transformative medicines.
Critics warn that after initial enthusiasm fades, funding ARPA-H could cut into NIH’s budget. Numerous stocks were negatively influenced by quarterly financial results announced during May.
Antibody-Drug Conjugates
Seagen and Astellas announced updated results from two trials on Padcev
The partners announced updated results from two clinical trials examining Padcev (enfortumab vedotin-ejfv) alone (EV-201 Cohort 2) and Padcev in combination with Keytruda (EV-103 Cohort A) in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy. The data will be presented at ASCO.
Interleukin-15 and Interleukin-2
ImmunityBio announced positive results of Anktiva with Rituxan in relapsed NHL patients
ImmunityBio announced publication of results from its Phase 1 study evaluating Anktiva (N-803), its IL-15 superagonist, in combination with Rituxan, an anti-CD20 monoclonal antibody therapy, in patients with indolent NHL, who had relapsed or were refractory after two lines of therapy.
Cell Therapies
Autolus presented new data on AUTO1 in relapsed or refractory indolent B cell lymphomas
Autolus has linked its CD19 CAR-T to a 100% complete response rate in a small indolent B-cell lymphoma trial. AUTO1 drove the responses without causing any grade 3 or worse cytokine release syndrome, sending shares in the biotech up 35%.
Other Innovative Treatment Areas
Approvals: FDA grants accelerated approval to Keytruda for HER2-positive gastric cancer
FDA granted accelerated approval to Keytruda in combination with Herceptin, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma.
Other Innovative Treatment Areas
Clinical: LAG3 to steal the spotlight from TIGIT at this year’s ASCO
The ASCO conference is set to deliver promising readouts for several compounds targeting LAG3 including data from BMS that could lead to the first registrational filing for a next-generation checkpoint blocker.
Sdílet na sociálních sítích